Ricciuto A, et al. - Experts sought to examine whether subclinical endoscopic and histologic inflammation could account for the increased risk of colorectal cancer in patients with primary sclerosing cholangitis-inflammatory bowel disease (PSC-IBD). They further explored if these patients had increased fecal levels of calprotectin (a marker of inflammation). Based on pediatric ulcerative colitis activity index (PUCAI) scores, children with PSC-IBD in clinical remission had a significantly higher risk of active endoscopic and histologic disease than children with colitis without PSC. In pediatric patients with PSC-IBD, fecal levels of calprotectin correlated with endoscopic findings; levels below 93 μg/g were associated with mucosal healing.